• Most Popular
  • Most Shared

UPDATE 1-Savient: One death in gout trial was in treatment arm

Thu Feb 28, 2008 5:35pm EST

Stocks

   

(Adds details)

Stocks

Feb 28 (Reuters) - Savient Pharmaceuticals Inc (SVNT.O) said one death in the late-stage trials of its gout drug, Puricase, was in a patient assigned to the group that received the treatment.

Shares of the company fell almost 5 percent to $23 after the bell. They closed at $24.16 Thursday on Nasdaq.

Two deaths occurred in patients assigned to receive a dummy drug, Savient said in a statement. (Reporting by Varsha Tickoo in Bangalore; Editing by Himani Sarkar)

Stocks


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
A hiring sign hangs in a window at PETCO in Falls Church, Virginia June 5, 2009.REUTERS/Kevin Lamarque

Dust off your resumes

Employers say they'll be adding headcount in the coming year. Here's where the jobs will be.  Full Article 

ECONOMY
Tiger Woods blows on his putter on the 10th hole during final round play of the Tournament Players Championship golf tournament at the TPC at Sawgrass in Ponte Vedra, Florida May 13, 2007.

Tiger's $12 billion scandal?

Shareholders of Tiger Woods' sponsors discover that along with the upside, there are big downside risks, too, a study shows.  Full Article 

Sports